



pharmaceuticals ltd.

Registered & Corporate Office :

Plot No. 19-111, Road No. 71,
Opp. Bharatiya Vidya Bhavan Public School,
Jubilee Hills Hyderabad - 500 096.Telangana. INDIA,
Tel : +91-40-6628 8888, Fax : +91-40-2355 1401
CIN : L24239AP1987PLC008066
Email : info@smspharma.com, www.smspharma.com

Date: 14th May, 2016

To,
The Managers,
Corporate Filings Department,
Bombay Stock Exchange Limited,
Phiroze Jeejeebhoy Towers,
Dalal Street,
Mumbai- 400 001

The Managers,
Listing Compliance Department,
National Stock Exchange of India Ltd.
Exchange Plaza, Plot no. C/1, G Block,
Bandra-Kurla Complex, Bandra (E),
Mumbai - 400 051.

Security Code: 532815

Symbol: SMSPHARMA

Subject: Outcome of the Board Meeting held on 14th May, 2016.

Dear Sir/Madam,

Pursuant to the Regulation 33 & 47 read with the Schedule III of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 and further to our letter dated 5th May, 2016 we would like to inform you that the Board of Directors of the Company at their meeting held on today, have approved the Audited Financial Statements of the Company for the Financial Year ended on 31st March, 2016. In terms of the above, we are enclosing herewith the following:

1. Audited Standalone Financial Statement for the year ended on 31st March, 2016.
2. Unaudited Standalone Financial Statement for the Quarter ended on 31st March, 2016.
3. Audited Consolidated Financial Statement for the year ended on 31st March, 2016.
4. 'Form - A' for Audited Standalone and Consolidate Financial Statement.
5. Auditor's Report for Audited Standalone and Consolidate Financial Statement.

The Board of Directors has recommended dividend a final dividend of Rs. 0.20/- (i.e. 20%) per equity share of Rs. 1/- face value, aggregating of Rs. 1,69,30,406/- which shall be paid within 30 days after the conclusion of the Annual General meeting, subject to the approval of the shareholders of the Company.

Please take the above intimation on your records.

Yours Faithfully,

For SMS Pharmaceuticals Limited

Saurav Roy
Company Secretary



pharmaceuticals ltd.

Registered & Corporate Office :

Plot No. 19-111, Road No. 71,

Opp. Bharatiya Vidya Bhavan Public School,

Jubilee Hills Hyderabad - 500 096.Telangana. INDIA,

Tel : +91-40-6628 8888, Fax : +91-40-2355 1401

CIN : L24239AP1987PLC008066

Email : info@smspharma.com, www.smspharma.com

Form A

[Under SEBI (LODR) Reg. 33(3)(d)]

(For audit report with unmodified opinion on
Audited Standalone Financial Statement)

Sl. No.	Particulars	
1.	Name of the company	SMS Pharmaceuticals Limited
2.	Annual financial statements for the year ended	31 st March, 2016
3.	Type of Audit observation	Unmodified
4.	Frequency of observation	Not Applicable

For SMS PHARMACEUTICALS LIMITED

For RAMBABU & Co.

Chartered Accountants

Firm Reg. No. 002976S

Ramesh Babu Potluri
Chairman &
Managing Director
DIN: 00166381

N. Rajendra Prasad
Chief Financial
Officer

P. Sarath Kumar
Audit Committee
Chairman
DIN: 01456746

Ravi Ram Babu
Statutory
Auditor
M. No.: 18541

Place: Hyderabad

Date: 14th May, 2016


SMS PHARMACEUTICAL LIMITED

Regd. Office: Plot No.19-III, Opp. BVBP School, Road No.71, Jubilee Hills, Hyderabad - 500 096


Statement of Audited Financial Results for the Quarter Ended 31st March, 2016

(Rs. In Lakhs)

S.No.	Particulars	Quarter Ended			9 Months Ended	Year Ended	Year Ended
		31-03-2016	31-12-2015	31-03-2015	31-12-2015	31-03-2016	31-03-2015
		(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	Audited	Audited
1	Income from Operations						
	(a) Net sales/Income from Operations	15,722.39	14,378.59	14,694.83	39,884.72	55,607.10	53,604.12
	(b) Other Operating Income	1,458.37	1,167.46	1,111.69	3,253.86	4,712.23	4,324.46
	Total Income from Operations (net)	17,180.76	15,546.05	15,806.52	43,138.58	60,319.34	57,928.58
2	Expenses						
	(a) Cost of materials consumed	10,639.05	10,453.59	10,368.82	29,306.28	39,945.32	38,841.06
	(b) Purchases of stock-in-trade	-	-	-	-	-	21.78
	(c) Changes in inventories of finished goods work-in-progress and stock-in trade	443.72	(422.98)	(205.26)	(1,407.65)	(963.93)	(315.02)
	(d) Employee Benefits Expense	1,090.40	910.58	912.09	2,720.91	3,811.31	3,167.13
	(e) Depreciation and amortisation expense	523.81	480.14	464.15	1,419.49	1,943.30	1,716.61
	(f) Other expenses	2,574.76	2,091.85	1,965.98	6,032.32	8,607.08	7,587.58
	Total - (a to f)	15,271.74	13,513.18	13,505.78	38,071.34	53,343.08	51,019.13
3	Profit from Operations before Other Income, finance cost and Exceptional Items (1) - (2)	1,909.02	2,032.87	2,300.74	5,067.23	6,976.25	6,909.45
4	Other Income	86.47	140.41	583.14	274.32	360.79	1,631.99
5	Profit / (Loss) from ordinary activities before finance costs and exceptional items (3)+(4)	1,995.49	2,173.28	2,883.88	5,341.56	7,337.05	8,541.44
6	Finance costs	451.67	378.49	515.30	1,258.14	1,709.81	1,793.09
7	Profit / (Loss) from ordinary activities after finance costs but before exceptional items (5)+(6)	1,543.82	1,794.79	2,368.58	4,083.42	5,627.24	6,748.35
8	Exceptional items	-	-	-	-	-	-
9	Profit / (Loss) from Ordinary Activities before Tax (7)+(8)	1,543.82	1,794.79	2,368.58	4,083.42	5,627.24	6,748.35
10	Tax Expenses	250.99	692.34	1,334.17	1,212.34	1,463.32	3,223.90
11	Net Profit / (Loss) from ordinary activities after Tax (9)-(10)	1,292.84	1,102.46	1,034.41	2,871.08	4,163.92	3,524.45
12	Extraordinary items (net of Tax Expense Rs. ... in lakhs)	-	-	-	-	-	-
13	Net Profit / (Loss) for the period (11) -(12)	1,292.84	1,102.46	1,034.41	2,871.08	4,163.92	3,524.45
14	Share of profit / (loss) of associates*						
15	Minority Interest*						
16	Net Profit / (Loss) after taxes, minority interest and share of profit / (loss) of associates (13+14+15)*	1,292.84	1,102.46	1,034.41	2,871.08	4,163.92	3,524.45
17	Paid-up equity share capital Rs.1/- per share	84,652,030	84,652,030	84,652,030	84,652,030	84,652,030	84,652,030
18	Reserves excluding Revaluation Reserves as per balance sheet of previous accounting year	-	-	-	-	28,589.63	24,629.48
19.i	Earning Per Share (before extraordinary items) (of Rs. 1 / each) (not annualised)	1.53	1.30	1.22	3.39	4.92	4.16
	(a) Basic						
	(b) Diluted						
19.ii	Earning Per Share (after extraordinary items) (of Rs. 1/ each) (not annualised)	1.53	1.30	1.22	3.39	4.92	4.16
	(a) Basic						
	(b) Diluted						




PARTICULARS OF SHARE HOLDING					
Public Shareholding					
- Number of Shares	30,579,180	30,579,180	3,054,760	30,579,180	3,054,760
- Percentage of Shareholding	36.12	36.12	36.09	36.12	36.09
Promoters and Promoters Group Shareholding**					
a) Pledged/Encumbered					
- Number of Shares	-	-	-	-	-
- Percentage of Shares (as a % of the total shareholding of promoter and promoter group)	-	-	-	-	-
- Percentage of Shares (as a % of the total share capital of the company)	-	-	-	-	-
b) Non-encumbered	54,072,850	54,072,850	5,410,443	54,072,850	5,410,443
- Number of Shares					
- Percentage of Shares (as a % of the total shareholding of promoter and promoter group)	100	100	100.00	100	100
- Percentage of Shares (as a % of the total share capital of the company)	63.88	63.88	63.91	63.88	63.91



Statement of Assets & Liabilities as at 31st March, 2016

(Rs.in Lakhs)

Sr.No.	Particulars	As at 31.03.2016 Audited	As at 31.03.2015 Audited
A	<u>EQUITY AND LIABILITIES</u>		
1	Shareholders' Funds		
	(a) Share Capital	846.52	846.52
	(b) Reserves & Surplus	28,589.63	24,629.48
	Sub-Total -Shareholders' funds	29,436.15	25,476.00
2	Non-Current Liabilities		
	(a) Long Term Borrowings	11,322.50	8,185.41
	(b) Deffered Tax Liability (Net)	4,490.04	3,572.81
	(c) Long Term Provisions	343.38	288.95
	Sub-Total -Non-Current Liabilities	16,155.91	12,047.17
3	Current Liabilities		
	(a) Short Term Borrowings	7,274.74	6,984.55
	(b) Trade Payables	8,440.28	6,100.08
	(c) Other Current Liabilities	4,037.40	2,222.23
	(d) Short Term Provisions	290.11	1,196.89
	Sub-Total - Current Liabilities	20,042.54	16,503.75
	TOTAL - EQUITY AND LIABILITIES	65,634.60	54,026.92
B	<u>ASSETS</u>		
1	Non-Current Assets		
	(a) Fixed Assets	38,315.07	30,596.91
	(b) Non Current Investments	2,126.90	1,322.81
	(c) Long Term Loans & Advances	437.40	1,922.78
	Sub-Total - Non-Current Assets	40,879.37	33,842.50
2	Current Assets		
	(a) Inventories	11,268.37	8,602.05
	(b) Trade Receivables	6,108.77	5,920.17
	(c) Cash and Cash Equivalents	1,508.24	636.37
	(d) Short Term Loans & Advances	2,251.98	1,062.41
	(e) Other Current Assets	3,617.88	3,963.42
	Sub-Total - Current Assets	24,755.23	20,184.42
	TOTAL ASSETS	65,634.60	54,026.92



Particulars	3 Months ended 31-03-2016
INVESTOR COMPLAINTS	
Pending at the beginning of the quarter	Nil
Received during the quarter	1
Disposed of during the quarter	1
Remaining unresolved at the end of the quarter	Nil

Notes:

The above results were reviewed by the Audit Committee on 14th May, 2016 and taken on record by the Board of Directors at its meeting held on 14th May, 2016 and have been audited by the Statutory Auditors of the company.

The Company's business activity falls within a single primary business segment. Hence segment reporting is not applicable.

During the year under review, the equity shares having face value of Rs.10/- each has been sub-divided into Rs.1/- each, accordingly the number of shares and earnings per share for the previous period/quarters have been restated

Tax expenses for the year ending 31.03.2016 of Rs.1,463.32 Lakhs includes deferred tax liability amount of Rs.917.23 Lakhs

Figures of last quarter are balancing figures between audited figures in respect of full financial year and the published year -to- date figures up to 3rd quarter of the financial year.


All accounting policies are followed consistently.

Figures of previous periods have been regrouped / rearranged wherever necessary.

Place: Hyderabad

Date : 14-05-2016

For SMS Pharmaceuticals Limited

Ramesh Babu Potluri
Chairman and Managing Director

Auditor's Report on Financial Results of the Company Pursuant to the Regulation 33 of Securities and Exchange Board of India (LODR) Regulations, 2015

To

The Board of Directors
SMS PHARMACEUTICALS LIMITED
Hyderabad.

We have audited the financial results of M/s. SMS PHARMACEUTICALS LIMITED for the year ended 31st March, 2016 attached herewith, being submitted by the company pursuant to the requirement of Regulation 33 of Securities and Exchange Board of India (LODR) Regulations, 2015. These financial results have been prepared on the basis of the interim financial statements, which are the responsibility of the company's management. Our responsibility is to express an opinion on these financial results based on our audit of such interim financial statements, which have been prepared in accordance with the recognition and measurement principles laid down in Accounting Standard (AS) 25, Interim Financial Reporting specified under section 133 of the Companies Act, 2013 read with Rule 7 of the Companies (Accounts) Rules, 2014 and other accounting principles generally accepted in India.


We conducted our audit in accordance with the auditing standards generally accepted in India. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial results are free of material misstatement(s). An audit includes examining, on a test basis, evidence supporting the amounts disclosed as financial results. An audit also includes assessing the accounting principles used and significant estimates made by management. We believe that our audit provides a reasonable basis for our opinion.

In our opinion and to the best of our information and according to the explanations given to us these financial results:

- (i) are presented in accordance with the requirements of Regulation 33 of Securities and Exchange Board of India (LODR) Regulations, 2015 in this regard; and
- (ii) give a true and fair view of the net profit and other financial information for the year from April 1, 2015 to March 31, 2016.

Place : Hyderabad
Date : 14-05-2016.

For **Rambabu & Co.,**
Chartered Accountants
Firm Regn. No. 002976S



RAVI RAMBABU
Partner
M.No. 018541.





pharmaceuticals ltd.

Registered & Corporate Office :

Plot No. 19-111, Road No. 71,

Opp. Bharatiya Vidya Bhavan Public School,

Jubilee Hills Hyderabad - 500 096.Telangana. INDIA,

Tel : +91-40-6628 8888, Fax : +91-40-2355 1401

CIN : L24239AP1987PLC008066

Email : info@smspharma.com, www.smspharma.com

Form A

[Under SEBI (LODR) Reg. 33(3)(d)]

(For audit report with unmodified opinion on
Audited Consolidated Financial Statement)

Sl. No.	Particulars	
1.	Name of the company	SMS Pharmaceuticals Limited
2.	Annual financial statements for the year ended	31 st March, 2016
3.	Type of Audit observation	Unmodified
4.	Frequency of observation	Not Applicable

For SMS PHARMACEUTICALS LIMITED

For RAMBABU & Co.

Chartered Accountants

Firm Reg. No. 002976S

Ramesh Babu Potluri
Chairman &
Managing Director
DIN: 00166381

N. Rajendra Prasad
Chief Financial
Officer

P. Sarath Kumar
Audit Committee
Chairman
DIN: 01456746


Ravi Ram Babu
Statutory
Auditor
M. No.: 18541

Place: Hyderabad

Date: 14th May, 2016

SMS PHARMACEUTICAL LIMITED
 Regd. Office: Plot No.19-III, Opp. BVBP School, Road No.71, Jubilee Hills, Hyderabad - 500 096
 Consolidated Audited Financial Results for the Year Ended 31st March, 2016

S.No.	Particulars	Year Ended
		31-03-2016
		Audited
1	Income from Operations	
	(a) Net sales/Income from Operations	55,607.10
	(b) Other Operating Income	4,712.23
	Total Income from Operations (net)	60,319.34
2	Expenses	
	(a) Cost of materials consumed	39,945.32
	(b) Purchases of stock-in-trade	-
	(c) Changes in inventories of finished goods work-in-progress and stock-in trade	(963.93)
	(d) Employee Benefits Expense	3,811.31
	(e) Depreciation and amortisation expense	1,943.30
	(f) Other expenses	8,607.08
	Total - (a to f)	53,343.08
3	Profit from Operations before Other Income, finance cost and Exceptional Items (1) - (2)	6,976.25
4	Other Income	360.79
5	Profit / (Loss) from ordinary activities before finance costs and exemptional items (3)+(4)	7,337.05
6	Finance costs	1,709.81
7	Profit / (Loss) from ordinary activities after finance costs but before exemptional items (5)+(6)	5,627.24
8	Exceptional items	-
9	Profit / (Loss) from Ordinary Activities before Tax (7)+(8)	5,627.24
10	Tax Expenses	1,463.32
11	Net Profit / (Loss) from ordinary activities after Tax (9)-(10)	4,163.92
12	Extraordinary items (net of Tax Expense Rs. ... in lakhs)	-
13	Net Profit / (Loss) for the period (11) -(12)	4,163.92
14	Share of profit / (loss) of associates*	(74.71)
15	Minority Interest*	-
16	Net Profit / (Loss) after taxes, minority interest and share of profit / (loss) of associates (13+14+15)*	4,089.21
17	Paid-up equity share capital Rs.1/- per share	84,652,030
18	Reserves excluding Revaluation Reserves as per balance sheet of previous accounting year	28,513.77
19.i	Earning Per Share (before extraordinary items) (of Rs. 1 / each) (not annualised)	4.83
	(a) Basic	
	(b) Diluted	
19.ii	Earning Per Share (after extraordinary items) (of Rs. 1/ each) (not annualised)	4.83
	(a) Basic	
	(b) Diluted	



A PARTICULARS OF SHARE HOLDING		
1	Public Shareholding	
	- Number of Shares	30,579,180
	- Percentage of Shareholding	36.12
2	Promoters and Promoters Group Shareholding**	
a)	Pledged/Encumbered	
	- Number of Shares	-
	- Percentage of Shares (as a % of the total shareholding of promoter and promoter group)	-
	- Percentage of Shares (as a % of the total share capital of the company)	-
b)	Non-encumbered	54,072,850
	- Number of Shares	100
	- Percentage of Shares (as a % of the total shareholding of promoter and promoter group)	100
	- Percentage of Shares (as a % of the total share capital of the company)	63.88

Statement of Consolidated Assets & Liabilities as at 31st March, 2016

Sr.No.	Particulars	As at 31.03.2016 Audited
A	<u>EQUITY AND LIABILITIES</u>	
1	Shareholders' Funds	
	(a) Share Capital	846.52
	(b) Reserves & Surplus	28,513.77
	Sub-Total -Shareholders' funds	29,360.29
2	Non-Current Liabilities	
	(a) Long Term Borrowings	11,322.50
	(b) Deferred Tax Liability (Net)	4,490.04
	(c) Long Term Provisions	343.38
	Sub-Total -Non-Current Liabilities	16,155.91
3	Current Liabilities	
	(a) Short Term Borrowings	7,274.74
	(b) Trade Payables	8,440.28
	(c) Other Current Liabilities	4,037.40
	(d) Short Term Provisions	290.11
	Sub-Total - Current Liabilities	20,042.54
	TOTAL - EQUITY AND LIABILITIES	65,558.74
B	<u>ASSETS</u>	
1	Non-Current Assets	
	(a) Fixed Assets	38,315.07
	(b) Non Current Investments	2,051.04
	(c) Long Term Loans & Advances	437.40
	Sub-Total - Non-Current Assets	40,803.51
2	Current Assets	
	(a) Inventories	11,268.37
	(b) Trade Receivables	6,108.77
	(c) Cash and Cash Equivalents	1,508.24
	(d) Short Term Loans & Advances	2,251.98
	(e) Other Current Assets	3,617.88
	Sub-Total - Current Assets	24,755.23
	TOTAL ASSETS	65,558.74




	Particulars	3 Months ended 31-03-2016
B	INVESTOR COMPLAINTS	
	Pending at the beginning of the quarter	Nil
	Received during the quarter	1
	Disposed of during the quarter	1
	Remaining unresolved at the end of the quarter	Nil

Notes:

1. The above consolidated results were reviewed by the Audit Committee on 14th May, 2016 and taken on record by the Board of Directors at its meeting held on 14th May, 2016 and have been audited by the Statutory Auditors of the company.
2. The results include the results of M/s VKT Pharma Private Ltd an Associate Company. The company holds 34.33% in equity of the said Associate Company.
3. VKT Pharma Pvt Ltd is considered as associate of the company for consolidation during the financial year 2015-16. Hence, no comparative figures of previous year are available.
3. Consolidated Financial Statement from which these results have been derived have been prepared by applying Accounting Standard "AS" 23 "Accounting for Investments in Associates in Consolidated Financial Statements" applicable under the Companies (Accounts) Rules 2014.
4. Non Current Investments Includes value of Shares acquired in Associate Company and Good will thereon of Rs.357.10 Lakhs (Previous Year of Rs.4.89 Lakhs)
5. The Company's business activity falls within a single primary business segment during the Financial Year 2015-16. Hence segment reporting is not applicable.
6. During the year under review, the equity shares having face value of Rs.10/- each has been sub-divided into Rs.1/- each, accordingly the number of shares and earnings per share for the previous year have been restated
7. Tax expenses for the year ending 31.03.2016 of Rs.1,463.32 Lakhs includes deferred tax liability amount of Rs.917.23 Lakhs
8. Pursant to clause 41 of erstwhile listing agreement, the company has opted to publish the Standalone Result. However, both the Consolidated and Standalone Financial Results for the Year Ended 31.03.2016 will be submitted to the BSE & NSE where the Equity Shares of the company are listed.
8. All accounting policies are followed consistently.
9. Figures of previous periods have been regrouped / rearranged wherever necessary.

Place: Hyderabad
Date : 14-05-2016



For SMS Pharmaceuticals Limited

Ramesh Babu Potluri

Ramesh Babu Potluri
Chairman and Managing Director

Auditor's Report on Consolidated Financial Results of the Company Pursuant to the Regulation 33 of Securities and Exchange Board of India (LODR) Regulations, 2015

To
The Board of Directors
SMS PHARMACEUTICALS LIMITED
Hyderabad.

We have audited the Consolidated financial results M/s. SMS PHARMACEUTICALS LIMITED and its associate VKT Pharma Pvt. Ltd., which were audited by their statutory auditors for the year ended 31st March, 2016 attached herewith, being submitted by the company pursuant to the requirement of Regulation 33 of Securities and Exchange Board of India (LODR) Regulations, 2015. These Consolidated financial results have been prepared on the basis of the Consolidated interim financial statements, which are the responsibility of the company's management. Our responsibility is to express an opinion on these Consolidated financial results based on our audit of such interim financial statements, which have been prepared in accordance with the recognition and measurement principles laid down in Accounting Standard (AS) 25, Interim Financial Reporting specified under section 133 of the Companies Act, 2013 read with Rule 7 of the Companies (Accounts) Rules, 2014 and other accounting principles generally accepted in India.

We conducted our audit in accordance with the auditing standards generally accepted in India. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial results are free of material misstatement(s). An audit includes examining, on a test basis, evidence supporting the amounts disclosed as financial results. An audit also includes assessing the accounting principles used and significant estimates made by management. We believe that our audit provides a reasonable basis for our opinion.

In our opinion and to the best of our information and according to the explanations given to us these Consolidated financial results:

- (i) are presented in accordance with the requirements of Regulation 33 of Securities and Exchange Board of India (LODR) Regulations, 2015 in this regard; and
- (ii) give a true and fair view of the Consolidated net profit and other financial information for the year from April 1, 2015 to March 31, 2016

Place : Hyderabad
Date : 14-05-2016.

For **Rambabu & Co.,**
Chartered Accountants
Firm Regn. No.002976S



RAVI RAMBABU
Partner
M.No.018541

